Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Rigosertib has demonstrated therapeutic activity for patients with high-risk myelodysplastic syndrome (MDS) in clinical trials. However, the role of rigosertib in MDS has not been thoroughly characterized. In this study, we found out that rigosertib induced apoptosis, blocked the cell cycle at the G...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Feng, He, Qi, Li, Xiao, Chang, Chun-Kang, Wu, Ling-Yun, Zhang, Zheng, Liu, Li, Shi, Wen-Hui, Zhu, Yang, Zhao, You-Shan, Gu, Shu-Cheng, Fei, Cheng-Ming, Guo, Juan, Wu, Dong, Zhou, Liyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255183/
https://www.ncbi.nlm.nih.gov/pubmed/25472472
http://dx.doi.org/10.1038/srep07310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255183/
https://www.ncbi.nlm.nih.gov/pubmed/25472472
http://dx.doi.org/10.1038/srep07310

Ejemplares similares